FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:600-601 August 31, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Feagan, B. G. PubMed Citation

To the Editor: Feagan et al. (Feb. 2 issue)¹ found that in a group of patients with chronically active Crohn's disease, methotrexate was more effective than placebo in improving symptoms and reducing requirements for prednisone. Further discussion is needed of the role of early treatment with mercaptopurine, rather than methotrexate, for sick patients with Crohn's disease.

Clinical remission after 16 weeks in 39.4 percent of the patients in the methotrexate group, as compared with 19.1 percent of patients in the placebo group, is less impressive than our 67 percent success rate with mercaptopurine (as compared with 8 percent with placebo, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., Hanauer, S. B., McDonald, J. W.D., The North American Crohn's Study Group Investigato, (2000). A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. NEJM 342: 1627-1632 [Abstract] [Full Text]